Therefore, BCL-2 inhibition is most likely to be effective in the cluster 5 with extranodal ABC and cluster 3 with GCB, which exhibited BCL-2 overexpression plus frequent mutations of CD79B and MYD88L265P (Fig. 4), or frequent mutations in epigenetic enzymes (e.g., KMT2D, CREBBP, and EZH2), BCL-2 and PTEN, respectively, as defined by Chapuy et al. [86]. Here, CD79B is linked to aneurysmal bone cyst.